Table 1 Representative clinical trials of Mirvetuximab Soravtansine-Gynx in ovarian epithelial cancers
From: Mirvetuximab soravtansine: current and future applications
Study name | Clinical trial information | Study detail | Patients | > 3 previous lines of therapy | Previous bevacizumab exposure | Previous PARPi exposure | ORR | Complete response | Partial response | Stable disease | Progressive disease | Unknown | mDOR | PFS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N/A [5] | NCT01609556 | Phase I | 46 pts receiving mirvetuximab | > 50%* | NR | NR | 26.1% | 1% | 11% | 28% | 4% | 2% | 19.1 weeks | 4.8 |
FORWARD I [6] | NCT02631876 | Phase III | 366 pts (243 receiving mirvetuximab) | 86 (34%) | 121 (48.8%) | 44 (17.7%) | 22% | NR | NR | NR | NR | NR | 5.7 months | 4.1 |
SORAYA [8] | NCT04296890 | Phase II | 106 pts receiving mirvetuximab | 54 (51%) | 106 (100%) | 51 (48%) | 30.2% | 5 (4.8%) | 29 (27.6%) | 48 (45.7%) | 20 (19.0%) | 3 (2.9%) | NR | 5.5 |
FORWARD II [7] | NCT02606305 | Phase Ib/II | 94 pts receiving mirvetuximab plus bevacizumab | 49 (52%) | 55 (59%) | 25 (27%) | 44% | 5 (6%) | 36 (38%) | 44 (47%) | 8 (9%) | 1 (1%) | 9.7 months | 8.2 |
MIRASOL‡ [9] | NCT04209855 | Phase III | 227 pts receiving mirvetuximab | 105 (46%) | 138 (61%) | 124 (55%) | 42% | 12 (5%) | 84 (37%) | 86 (38%) | 31 (14%) | 14 (6%) | NR | 5.9 |